KRAS and acute myeloid leukemia: However, a recent study by Wu et al. showed that KMT2Ar AML patients harboring KRAS mutations had significantly worse 2-year OS and higher 2-year cumulative incidence of relapse (CIR) compared to those with wild-type KRAS, while NRAS and FLT3 mutations were not significantly associated with differences in OS or CIR [56].